Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
← catalyst calendarNCT06029972 · readout ≤ 165 d
Sponsored by Gilead Sciences (industry) · GILD — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
176estimated
Sites
129
Countries
Australia, Austria, Belgium +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-05 | actual | When the study began enrolling |
| Primary completion | Jan 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2023-09-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Ulcerative Colitis
Interventions
- Drug: Tilpisertib Fosmecarbil — also filed as GS-5290
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFProportion of Participants Achieving Clinical Response Per Modified Mayo Clinic Score at Week 12
measured Week 12
Permalink · GILD's whole pipeline · Catalyst calendar · Every registered study · What changed